Atrium Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNA research report →
Range $15 – $25
Price Chart
About the company
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy.
- CEO
- Kathleen Gallagher
- IPO
- 2026
- Employees
- 511
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on RNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $149.27M
- P/E
- -1.70
- PEG
- 0.01
- P/S
- 3.88
- P/B
- 0.58
- EV/EBITDA
- -1.18
- Div Yield
- 0.00%
- Gross Margin
- 42.18%
- Op Margin
- -243.60%
- Net Margin
- -229.67%
- ROE
- -41.42%
- ROIC
- -39.40%
Latest fiscal year · YoY change
- Revenue
- $18.62M+0.0%
- Gross Profit
- $18.62M+0.0%
- Op Income
- $-76,814,000
- Net Income
- $-76,684,000+0.0%
- EPS
- $-4.48+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $16.77
- 52W Low
- $6.36
- 50D MA
- $8.25
- 200D MA
- $11.75
- Beta
- 0.37
- RSI (14)
- 34
- Avg Volume
- 295.03K
No earnings-call transcripts are available for RNA yet.
- Free Float
- 90.4%
- Shares Outstanding
- 21.57M
- Float Shares
- 19.51M
of shares held by institutions
159 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 13.65M | ▲ 429.49K |
| Oconnor, A Distinct Business Unit Of Ubs Asset Management Americas (LLC) | 3.72M | ▲ 3.72M |
| Sessa Capital Im, L.P. | 1.50M | 0 |
| Blackrock, Inc. | 1.22M | ▼ 228.95K |
| Kryger Capital Ltd | 1.05M | ▲ 1.05M |
| Vanguard Capital Management LLC | 730.03K | ▼ 805 |
| Price T Rowe Associates Inc | 640.03K | ▼ 832.95K |
| O'Connor Alternative Investments, LLC | 559.14K | ▼ 37.88K |
| Bracebridge Capital, LLC | 524.48K | ▲ 385.24K |
| Tig Advisors, LLC | 506.93K | ▼ 54.61K |
| Bank Of America Corp | 467.82K | ▲ 334.99K |
| Two Sigma Investments, LP | 427.38K | ▲ 81.90K |
Held by 131 ETFs
Biggest fund positions in RNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Younis Husam | other | 11,216 |
| Sep 18, 26 | Hughes Steven George | other | 21,459 |
| Sep 18, 26 | Flanagan W. Michael | other | 22,812 |
| Sep 18, 26 | Boyce Sarah | other | 126,418 |
| Sep 18, 26 | Kenney Stephanie | other | 2,375 |
| Sep 18, 26 | Gallagher Kathleen P. | other | 11,632 |
| Sep 18, 26 | Winslow Brendan R. | other | 6,742 |
| Sep 18, 26 | Hoyos Rocio Martin | other | 8,320 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RNA coverage
Recent articles, reports, and earnings notes.
No research on RNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNA report →Atrium Therapeutics Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 12
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
prnewswire.com · Nov 2
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
prnewswire.com · Oct 27
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Oct 20
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
prnewswire.com · Oct 20
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement
defenseworld.net · Oct 10
Atrium Therapeutics Announces $50 Million Private Placement
prnewswire.com · Oct 8
Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.